AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. IDYA
  4. [Form 4] IDEAYA Biosciences, Inc. Insider Trading Activity

[Form 4] IDEAYA Biosciences, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

IDEAYA Biosciences (IDYA) Director Jeffrey Stein received a new stock option grant on June 24, 2025. The grant consists of 20,000 stock options with an exercise price of $21.78 per share.

Key details of the option grant:

  • Expiration date: June 24, 2035
  • Vesting schedule: 100% vests on earlier of (i) first anniversary of grant date or (ii) immediately before next Annual Meeting
  • Vesting contingent on continued Board service

This Form 4 filing, signed by Attorney-in-Fact Andres Ruiz Briseno on June 26, 2025, represents standard equity compensation for non-employee director service. The grant aligns the director's interests with shareholders through long-term equity ownership.

IDEAYA Biosciences (IDYA) Il direttore Jeffrey Stein ha ricevuto una nuova concessione di opzioni su azioni il 24 giugno 2025. La concessione comprende 20.000 opzioni su azioni con un prezzo di esercizio di 21,78 $ per azione.

Dettagli principali della concessione di opzioni:

  • Data di scadenza: 24 giugno 2035
  • Programma di maturazione: il 100% matura al primo tra (i) il primo anniversario della data di concessione o (ii) immediatamente prima della prossima Assemblea Annuale
  • La maturazione 猫 subordinata alla continuazione del servizio nel Consiglio

Questa comunicazione Form 4, firmata dall'Avvocato-in-Fatto Andres Ruiz Briseno il 26 giugno 2025, rappresenta una normale forma di compenso azionario per il servizio di un direttore non dipendente. La concessione allinea gli interessi del direttore con quelli degli azionisti attraverso la propriet脿 azionaria a lungo termine.

IDEAYA Biosciences (IDYA) El director Jeffrey Stein recibi贸 una nueva concesi贸n de opciones sobre acciones el 24 de junio de 2025. La concesi贸n consta de 20,000 opciones sobre acciones con un precio de ejercicio de $21.78 por acci贸n.

Detalles clave de la concesi贸n de opciones:

  • Fecha de vencimiento: 24 de junio de 2035
  • Calendario de adquisici贸n: 100% se adquiere en la fecha que ocurra primero entre (i) el primer aniversario de la fecha de concesi贸n o (ii) inmediatamente antes de la pr贸xima Junta Anual
  • La adquisici贸n est谩 condicionada a la continuidad del servicio en la Junta

Esta presentaci贸n del Formulario 4, firmada por el Apoderado Andres Ruiz Briseno el 26 de junio de 2025, representa una compensaci贸n est谩ndar en acciones para el servicio de un director no empleado. La concesi贸n alinea los intereses del director con los de los accionistas mediante la propiedad accionaria a largo plazo.

IDEAYA Biosciences (IDYA) 鞚挫偓 鞝滍攧毽� 鞀ろ儉鞚胳潃 2025雲� 6鞗� 24鞚� 靸堧鞖� 欤检嫕毵れ垬靹犿儩甓岇潉 攵�鞐皼鞎橃姷雼堧嫟. 鞚� 攵�鞐姅 欤茧嫻 21.78雼煬鞚� 頄夓偓 臧�瓴╈溂搿� 20,000欤�鞚� 欤检嫕鞓奠厴鞙茧 甑劚霅╇媹雼�.

鞓奠厴 攵�鞐潣 欤检殧 雮挫毄:

  • 毵岆鞚�: 2035雲� 6鞗� 24鞚�
  • 氩犾姢韺� 鞚检爼: (i) 攵�鞐澕搿滊秬韯� 1欤茧厔 霕愲姅 (ii) 雼れ潓 鞐半 欤检＜齑濏殞 歆侅爠 欷� 牍犽ジ 鞁滌爯鞐� 100% 氩犾姢韺�
  • 氩犾姢韺呾潃 鞚挫偓須� 歆�靻� 攴茧 臁瓣贝攵�

2025雲� 6鞗� 26鞚� 雽�毽澑 鞎堧摐霠堨姢 耄澊歃� 敫岆Μ靹鸽吀臧� 靹滊獏頃� 鞚� Form 4 鞝滌稖鞚� 牍勳儊攴� 鞚挫偓 靹滊箘鞀れ棎 雽�頃� 響滌 欤检嫕 氤挫儊鞛呺媹雼�. 鞚� 攵�鞐姅 鞛リ赴 欤检嫕 靻岇湢毳� 韱淀暣 鞚挫偓鞚� 鞚挫澋鞚� 欤检＜鞕� 鞚检箻鞁滍偟雼堧嫟.

IDEAYA Biosciences (IDYA) Le directeur Jeffrey Stein a re莽u une nouvelle attribution d'options d'achat d'actions le 24 juin 2025. L'attribution comprend 20 000 options d'achat avec un prix d'exercice de 21,78 $ par action.

D茅tails cl茅s de l'attribution d'options :

  • Date d'expiration : 24 juin 2035
  • Calendrier d'acquisition : 100 % acquis 脿 la premi猫re des deux dates suivantes : (i) le premier anniversaire de la date d'attribution ou (ii) imm茅diatement avant la prochaine Assembl茅e Annuelle
  • L'acquisition est conditionn茅e 脿 la poursuite du service au Conseil d'Administration

Ce d茅p么t du formulaire 4, sign茅 par le mandataire Andres Ruiz Briseno le 26 juin 2025, repr茅sente une compensation en actions standard pour le service d'un administrateur non salari茅. L'attribution aligne les int茅r锚ts du directeur avec ceux des actionnaires gr芒ce 脿 une d茅tention d'actions 脿 long terme.

IDEAYA Biosciences (IDYA) Direktor Jeffrey Stein erhielt am 24. Juni 2025 eine neue Aktienoptionszuteilung. Die Zuteilung umfasst 20.000 Aktienoptionen mit einem Aus眉bungspreis von 21,78 $ pro Aktie.

Wichtige Details der Optionszuteilung:

  • Ablaufdatum: 24. Juni 2035
  • Vesting-Plan: 100 % werden zum fr眉heren Zeitpunkt von (i) dem ersten Jahrestag des Zuteilungsdatums oder (ii) unmittelbar vor der n盲chsten Hauptversammlung unverfallbar
  • Vesting ist abh盲ngig von fortgesetztem Vorstandsdienst

Diese Form 4 Einreichung, unterzeichnet vom Bevollm盲chtigten Andres Ruiz Briseno am 26. Juni 2025, stellt eine standardm盲脽ige Aktienverg眉tung f眉r nicht angestellte Direktoren dar. Die Zuteilung richtet die Interessen des Direktors durch langfristigen Aktienbesitz mit denen der Aktion盲re aus.

Positive
  • None.
Negative
  • None.

IDEAYA Biosciences (IDYA) Il direttore Jeffrey Stein ha ricevuto una nuova concessione di opzioni su azioni il 24 giugno 2025. La concessione comprende 20.000 opzioni su azioni con un prezzo di esercizio di 21,78 $ per azione.

Dettagli principali della concessione di opzioni:

  • Data di scadenza: 24 giugno 2035
  • Programma di maturazione: il 100% matura al primo tra (i) il primo anniversario della data di concessione o (ii) immediatamente prima della prossima Assemblea Annuale
  • La maturazione 猫 subordinata alla continuazione del servizio nel Consiglio

Questa comunicazione Form 4, firmata dall'Avvocato-in-Fatto Andres Ruiz Briseno il 26 giugno 2025, rappresenta una normale forma di compenso azionario per il servizio di un direttore non dipendente. La concessione allinea gli interessi del direttore con quelli degli azionisti attraverso la propriet脿 azionaria a lungo termine.

IDEAYA Biosciences (IDYA) El director Jeffrey Stein recibi贸 una nueva concesi贸n de opciones sobre acciones el 24 de junio de 2025. La concesi贸n consta de 20,000 opciones sobre acciones con un precio de ejercicio de $21.78 por acci贸n.

Detalles clave de la concesi贸n de opciones:

  • Fecha de vencimiento: 24 de junio de 2035
  • Calendario de adquisici贸n: 100% se adquiere en la fecha que ocurra primero entre (i) el primer aniversario de la fecha de concesi贸n o (ii) inmediatamente antes de la pr贸xima Junta Anual
  • La adquisici贸n est谩 condicionada a la continuidad del servicio en la Junta

Esta presentaci贸n del Formulario 4, firmada por el Apoderado Andres Ruiz Briseno el 26 de junio de 2025, representa una compensaci贸n est谩ndar en acciones para el servicio de un director no empleado. La concesi贸n alinea los intereses del director con los de los accionistas mediante la propiedad accionaria a largo plazo.

IDEAYA Biosciences (IDYA) 鞚挫偓 鞝滍攧毽� 鞀ろ儉鞚胳潃 2025雲� 6鞗� 24鞚� 靸堧鞖� 欤检嫕毵れ垬靹犿儩甓岇潉 攵�鞐皼鞎橃姷雼堧嫟. 鞚� 攵�鞐姅 欤茧嫻 21.78雼煬鞚� 頄夓偓 臧�瓴╈溂搿� 20,000欤�鞚� 欤检嫕鞓奠厴鞙茧 甑劚霅╇媹雼�.

鞓奠厴 攵�鞐潣 欤检殧 雮挫毄:

  • 毵岆鞚�: 2035雲� 6鞗� 24鞚�
  • 氩犾姢韺� 鞚检爼: (i) 攵�鞐澕搿滊秬韯� 1欤茧厔 霕愲姅 (ii) 雼れ潓 鞐半 欤检＜齑濏殞 歆侅爠 欷� 牍犽ジ 鞁滌爯鞐� 100% 氩犾姢韺�
  • 氩犾姢韺呾潃 鞚挫偓須� 歆�靻� 攴茧 臁瓣贝攵�

2025雲� 6鞗� 26鞚� 雽�毽澑 鞎堧摐霠堨姢 耄澊歃� 敫岆Μ靹鸽吀臧� 靹滊獏頃� 鞚� Form 4 鞝滌稖鞚� 牍勳儊攴� 鞚挫偓 靹滊箘鞀れ棎 雽�頃� 響滌 欤检嫕 氤挫儊鞛呺媹雼�. 鞚� 攵�鞐姅 鞛リ赴 欤检嫕 靻岇湢毳� 韱淀暣 鞚挫偓鞚� 鞚挫澋鞚� 欤检＜鞕� 鞚检箻鞁滍偟雼堧嫟.

IDEAYA Biosciences (IDYA) Le directeur Jeffrey Stein a re莽u une nouvelle attribution d'options d'achat d'actions le 24 juin 2025. L'attribution comprend 20 000 options d'achat avec un prix d'exercice de 21,78 $ par action.

D茅tails cl茅s de l'attribution d'options :

  • Date d'expiration : 24 juin 2035
  • Calendrier d'acquisition : 100 % acquis 脿 la premi猫re des deux dates suivantes : (i) le premier anniversaire de la date d'attribution ou (ii) imm茅diatement avant la prochaine Assembl茅e Annuelle
  • L'acquisition est conditionn茅e 脿 la poursuite du service au Conseil d'Administration

Ce d茅p么t du formulaire 4, sign茅 par le mandataire Andres Ruiz Briseno le 26 juin 2025, repr茅sente une compensation en actions standard pour le service d'un administrateur non salari茅. L'attribution aligne les int茅r锚ts du directeur avec ceux des actionnaires gr芒ce 脿 une d茅tention d'actions 脿 long terme.

IDEAYA Biosciences (IDYA) Direktor Jeffrey Stein erhielt am 24. Juni 2025 eine neue Aktienoptionszuteilung. Die Zuteilung umfasst 20.000 Aktienoptionen mit einem Aus眉bungspreis von 21,78 $ pro Aktie.

Wichtige Details der Optionszuteilung:

  • Ablaufdatum: 24. Juni 2035
  • Vesting-Plan: 100 % werden zum fr眉heren Zeitpunkt von (i) dem ersten Jahrestag des Zuteilungsdatums oder (ii) unmittelbar vor der n盲chsten Hauptversammlung unverfallbar
  • Vesting ist abh盲ngig von fortgesetztem Vorstandsdienst

Diese Form 4 Einreichung, unterzeichnet vom Bevollm盲chtigten Andres Ruiz Briseno am 26. Juni 2025, stellt eine standardm盲脽ige Aktienverg眉tung f眉r nicht angestellte Direktoren dar. Die Zuteilung richtet die Interessen des Direktors durch langfristigen Aktienbesitz mit denen der Aktion盲re aus.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Stein Jeffrey
(Last) (First) (Middle)
C/O IDEAYA BIOSCIENCES, INC.
5000 SHORELINE COURT, SUITE 300
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IDEAYA Biosciences, Inc. [ IDYA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $21.78 06/24/2025 A 20,000 (1) 06/24/2035 Common Stock 20,000 $0 20,000 D
Explanation of Responses:
1. 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.
/s/ Andres Ruiz Briseno, as Attorney-in-Fact for Jeffrey Stein 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What stock options did IDYA director Jeffrey Stein receive on June 24, 2025?

Jeffrey Stein received 20,000 stock options with an exercise price of $21.78 per share. These options were granted on June 24, 2025, and will expire on June 24, 2035.

What are the vesting terms for Jeffrey Stein's IDYA stock options granted in June 2025?

The stock options will vest 100% on the earlier of: (i) the first anniversary of the grant date (June 24, 2026) or (ii) immediately prior to the next Annual Meeting following the grant date. Vesting is subject to Stein continuing his service on the Board through the vesting date.

Who filed the Form 4 for IDYA director Jeffrey Stein?

The Form 4 was signed by Andres Ruiz Briseno, acting as Attorney-in-Fact for Jeffrey Stein, on June 26, 2025.

What position does Jeffrey Stein hold at IDYA Biosciences?

According to the Form 4 filing, Jeffrey Stein serves as a Director on the Board of IDEAYA Biosciences, Inc. (IDYA).

How many IDYA shares could Jeffrey Stein acquire through the June 2025 option grant?

Through this stock option grant, Jeffrey Stein has the right to buy 20,000 shares of IDYA common stock at an exercise price of $21.78 per share.
Stock IDYA logo
Ideaya Biosciences

NASDAQ:IDYA

IDYA Rankings

#3025 Ranked by Market Cap
N/A Ranked by Dividends

IDYA Latest News

Jul 23, 2025
IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy
Jul 22, 2025
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC
Jul 21, 2025
IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event
Jun 27, 2025
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Jun 2, 2025
IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events

IDYA Latest SEC Filings

Jun 27, 2025
[Form 3] IDEAYA Biosciences, Inc. Initial Statement of Beneficial Ownership
Jun 27, 2025
[8-K] IDEAYA Biosciences, Inc. Reports Material Event
Jun 26, 2025
[Form 4] IDEAYA Biosciences, Inc. Insider Trading Activity
Jun 26, 2025
[Form 4] IDEAYA Biosciences, Inc. Insider Trading Activity
Jun 26, 2025
[Form 4] IDEAYA Biosciences, Inc. Insider Trading Activity

IDYA Stock Data

1.98B
86.79M
1.04%
109.56%
10.5%
Biotechnology
Pharmaceutical Preparations
United States
SOUTH SAN FRANCISCO